The FDA has expanded the approval of Jylamvo (methotrexate, Shorla Oncology) oral solution to include the treatment of children and adolescents with polyarticular juvenile idiopathic arthritis (pJIA) and acute lymphoblastic leukemia (ALL). This decision marks Jylamvo as the only oral liquid methotrexate formulation approved for both adult and pediatric indications currently available.
Addressing Unmet Needs in Pediatric Care
According to Shorla Oncology, this expanded approval represents a significant advancement in addressing the unmet needs within pediatric care for both oncology and autoimmune diseases. "This approval follows Jylamvo’s successful use in adult patients and represents a critical step forward in addressing the unmet needs of pediatric care in oncology and autoimmune diseases," said Sharon Cunningham, CEO of Shorla Oncology.
Jylamvo's Existing Approvals and Unique Features
Jylamvo was initially approved by the FDA in November 2022 for adult patients with acute lymphoblastic leukemia, mycosis fungoides, relapsed or refractory non-Hodgkin lymphoma, rheumatoid arthritis, and severe psoriasis. The oral solution features an orange flavor and includes a dedicated dosing syringe for accurate administration.
Rayna Herman, chief commercial officer of Shorla Oncology, highlighted the practical benefits of Jylamvo: "In addition to its palatable formulation, Jylamvo offers key differences over similar drugs, such as room temperature stability for 3 months after opening, which eliminates the need for refrigeration before dispensing and adds convenience for patients."
Implications for Patients and Healthcare Providers
The expanded approval of Jylamvo provides a convenient, patient-friendly alternative for both adult and pediatric patients in the United States, particularly those with limited treatment options. Its availability as an oral liquid formulation and its room temperature stability enhance ease of use and adherence to treatment regimens.
